Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach

#4163

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the tumors’ aberrant changes. However, the metabolic plasticity of pancreatic neuroendocrine tumors (pNET) is still unknown. pNETs are heterogeneous which makes their diagnosis, prognosis and therapeutic management difficult.

Aim(s): We aimed to assess the metabolomic profile of pNETs patients to understand metabolic deregulation and identify novel biomarkers with clinical potential.

Materials and methods: Plasma samples from 78 pNETs and 40 controls were profiled by LC−MS/MS and FIA-MS/MS targeted metabolomics analysis (Biocrates AbsoluteIDQp180kit). Explanatory multivariate statistical and unsupervised learning analysis were performed to evaluate metabolomic profiles. Finally, nonparametric comparison analysis was performed to select metabolites biomarker.

Conference:

Presenting Author:

Authors: Jannin A, Dessein A, Dabo S, Descat A, Vantyghem M,

Keywords: pancreatic NET, diagnostic biomarker, plasma metabolites, molecular pathways,